Drugs / KINE-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07324642 | May → Aug 2025 | — | Kine Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07343310 | Aug 2024 → Apr 2025 | polyneuropathy, inflammatory demyelinating, chronic | Kine Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07343323 | Nov 2021 → Jan 2023 | — | Kine Sciences Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KINE-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07324642 ↗ |
| Route | Intravenous | “intravenous infusion” NCT07324642 ↗ |